In the most recent Cardiovascular Outcomes for People Using Anticoagulation Strategies [74] trial, the role of factor Xa inhibition with Rvaroxaban was tested among chronic and stabilized patients with coronary artery disease (CAD) and in peripheral arterial disease (PAD) [74]. The gene discussed is F10; the disease is peripheral arterial disease.